“SmartChem is useful not only in sourcing of raw material, but also helps us in making the synthesis route, along with Literature search and patent search. This minimizes time and in turn has a direct impact on cost of the project”

-Research Head, one of the top chemical companies in Europe

“ROW2’s RouteDesign service has given us many Novel Route ideas for our target molecules. The diverse route ideas recommended in RouteDesign reports also act as excellent stimuli to our own thought process. I must add that ROW2 team is very responsive and follow strict security norms. We are using RouteDesign service satisfactorily for the past 3 years”.

-Director Technology, Process R & D Dept, One of the top 10 global pharmaceutical companies

“If you have an apple and I have an apple and we exchange these apples, then you and I will still have one apple. But if you have an idea and I have an idea and if we exchange these ideas, then each of us will have two ideas”
- George Bernard Shaw

“The web seminar sponsored by ROW2 Technologies on chiral synthesis was very interesting, gave information on up-to-date chemistry, and was well organized. I look forward to more seminars via web”

- Dr. William Nadler, Head of Chemical Synthesis, Industria Farmaceutica Serono, Italy

To get a copy of this Webseminar click here

Bonjour Mesdames et Messieurs

Welcome to CI2E Quarterly, France special! Since everyone was in the wonderful city of Paris this month for the CPhI Worldwide conference, how could ROW2 not be a part of it? In this issue we will bring to light some key opportunities of doing business in and with France.So put on you beret and get ready to take on France!

CI2E Quarterly is being shared with over 5000 "select" industry professionals in the life science and chemical industries and we pride ourselves in providing this informative, interactive and entertaining newsletter!

Developed by ROW2 Technologies, a company with expertise in synthetic organic chemistry and knowledge on the global chemical industry, CI2E Quarterly provides:

• News about ROW2 and its offerings of interest to you.
  
• Key articles and information on the pharmaceutical/chemical industries, written by renowned thought leaders.
  
• "My Forum", a unique opportunity to advertise your company's strengths, capabilities, achievements, etc. to ROW2's global customers and readers.
  
• Entertainment through interesting facts and fun trivia to make you laugh and relax a little during your busy day.
  

In this issue:

• ROW2 World: Updates on our company & offerings
• Featured Article: Business opportunities in France
• Links: to various other articles of interest
• MyForum: Rubamin Laboratories Ltd., an insight by Dr. C Prabhakar
• Humour: Read some interesting facts about France, enjoy chemistry Puns. Also participate in our Fun Trivia to win Prizes!

ROW2 World - This Quarter's Highlights:

ROW2 News

• Route2India Launched: If your challenge is to find the “Right and Credible” outsourcing partner/s from the fragmented and diverse Indian CRAMs industry then Route2India is the Right solution.
  
  Route2India: is a fully integrated and customized service which enables identification and evaluation of Custom Research / Custom Manufacturing companies in India.
  
  To know more about our Route2India offering and benefits
  to your organization, click here.
  
  
• Our Customers: During this calendar year, ROW2 acquired more customers to breach the landmark of serving 650 customers since its inception. Our customers now include 7
  of the top 10 Pharmaceutical companies, 4 of the top 5 Chemical manufacturers and 5 leading AgroScience firms.

We sincerely thank all our customers for their continued
trust and support.


• Upcoming events: ROW2 will be attending CPhI Mumbai
  on 1-3 December 2006 in Mumbai, India. More so you will
  be able to catch our Process Chemists at the New International Conference on Developing Chemical
  Processes for Active Pharmaceutical Ingredients on 13-14 December in Pune, India.
  
  
• Events: ROW2 attended the Organic Process Research & Development Conference on July 17-19 in Vancouver, Canada, CPhI worldwide on October 3-5 in Paris, France.
  
  

SmartChem News

• Elite Club Program: We recently launched our Elite Club Program for SmartChem subscribers. Our privileged customers* can now enjoy variety of rewards and privileges through this program. Eligibility for Elite Club Membership is based on various parameters like number of years of SmartChem subscription, SmartChem usage pattern and contacts referred to SmartChem etc. Rewards range from strolley bag, Ipod Nano to free additional SC license and many more!
  To know more about the Elite Club Program write to us here. *Conditions apply

• Referral Program to be Launched Soon: Our SmartChem subscribers can soon participate in ROW2's Win-Win Referral Program. By participating in this program, you can win valuable rewards for your organization. Our sales team will get in touch with you shortly to unfold this exciting program.

• Thanksgiving Celebration: Thanksgiving is just around the corner and this year ROW2 has a lot to be thankful for. We have seen an upsurge in SmartChem subscriptions with more than 25% of new subscriptions coming from references of our current customers. Today we are thankful to be serving over 650 customers. We appreciate the confidence you have shown in us. So on this joyous occasion of thanksgiving we would like to convey our most heart felt thanks to all our subscribers for their trust and support with a token of our appreciation.

RouteDesign News

• RouteDesign continues to make strides: We at ROW2 strongly believe that the best way to provide customized solutions to the dynamic needs of our customers is to regularly obtain customer’s feedback. With this sole objective, we bettered our RouteDesign feedback parameters last quarter to capture not only qualitative but also quantitative feedback. We thank our customers for their encouraging feedback. We are glad to share few of the responses here. 71% customers feel that Chemistry in RouteDesign exceeds their expectations.
  More than 90% customers accepted the fact that RouteDesign provided them with new route ideas that they had not considered before. Watch out our next newsletter for some more interesting responses!

• Process Research Chemists Day: Process Research Chemist is one of the most critical contributors to the product life cycle. We at ROW2 value the contribution of Process Research Fraternity in creating innovative solutions essential to a better, safer, longer and healthier life for people world over. We consider ourselves privileged as we get to serve process research chemists with our various offerings. As a gesture of our gratitude and appreciation to the Process Research fraternity, we will be celebrating “Process Research Chemists Day” on November 10, 2006 on the occasion of World Science Day.

• Web Seminar Recording: A recording of "Fascinating Excursions into Chiral Chemistry: An Insider's Perspective” a web seminar, which was hosted by ROW2 Technologies on June 1, 2006, is now available on the ROW2 Technologies site, click here to view it.
  
  If you have not viewed it as yet you are missing out on something!!

  Details for each of the above-mentioned activities will be sent through a separate communication to all our customers.

ROW2 Event Alerts

Events of interest in the next three months:




• InformEx China: 8 -9 November 2006, Guangzhou, China.

• Chemspec China: 29-30 November 2006, Shanghai, China.

• CPhI India: 1-3 December 2006, Mumbai, India

• Developing Chemical Process for Active Pharmaceutical

  Ingredients: 13-15 December 2006, Pune, India.
  (Special offer for 3 or more delegates)

  

Featured Article

France, the partner of choice for your entry to the European Biotech market!

Article by the Consulate General of France - Economic Mission and the Invest in France Agency.

France biotechnology: a strong healthcare focus – a winning bet in Foreign Direct Investments:

The French biotech industry concentrates 53% of its research in the health field. The sector has expanded its pipeline of drug candidates, with 195 candidates in therapeutic products alone under development in 2005, of which 87 are biological and chemical products in clinical trials (41 in phase I, 39 in phase II, and 7 in phase III).

Research, focusing primarily on as yet unmet medical needs, is aimed at developing effective treatments for the major
diseases of the century: cancer, AIDS, cardiovascular disease, obesity, diabetes and neurodegenerative disorders (Alzheimer's and others).

The 90-odd biodrugs sold in France today, generating Euros 2.2 billion in revenue, account for about 10% of the domestic pharmaceuticals market. In short, France holds the right cards to attract a substantial share of productive investments planned for 2007 to 2011, estimated to exceed $2 billion a year. Recently, the Swiss group Novartis picked Alsace as the location
for Europe's largest biotechnology-based drug production facility.

As biotechnology's major industrial, therapeutic and economic repercussions emerge, it has become a policy priority in France, following the example of the United States or Japan, but also up-and-coming countries in the sector like India and China.

To read the full article click here

ROW2 picks of the quarter

To keep track of the latest industry/chemistry news, our research and commercial teams review several journals, publications and websites per month. Here are some interesting picks, which will be of relevance to you. Let us know what you think of our selections!

Podcast: Overcoming Marketing Challenges
Published in: PharmaVoice, Sept 11, 2006 issue

This is a fascinating podcast on the marketing challenges of the pharmaceutical industry.

Farming out R&D
Published in: eyeforpharma.com, Sept 5, 2006 issue

An interesting article about how mid-sized pharma companies will see half their revenues will come from products outside their own pipeline. It also sheds light on how dealing with mid-sized pharma companies is advantageous for small discovery companies.

How to avoid Contract Manufacturing Disappointment
Published in: in-Pharma technologist.com, Sept 14, 2006 issue

Contract Manufacturing is on the lips of all pharmaceutical companies, but how does one avoid disappointment in the process. The key: Technology transfer and effective management.

Changing a drug to match drug delivery technology

Conventional drug delivery theory is tested with an unconventional one, by having a drug conform to a drug delivery platform.

Featured Article Cont'd.

France Biotechnology: a strong healthcare focus

Supportive Environment:
France offers a highly supportive environment to the development of the biotechnology industry

Grants up to 450 000 Euros to promote innovative start-ups: A competitive grants program, mainspring of France's innovation policy, is designed to promote innovative start-ups. Since its launch in 1999, some 700 new start-ups have emerged; of which one fourth operate in the life sciences.

Up to 8M Euros tax credit for research per company per year Another measure to support R&D was government assistance via the CIR (Crédit d'Impôt Recherche). This tax credit for research, fixed at a maximum Euros 8 million per year and per company since 2004.

A unique vehicle for business angels insuring 10 years tax exemption To encourage venture capital investment in emerging companies, the government set up a vehicle in 2004 specifically tailored to business angels. This new legal framework, the Société Unipersonnelle d'Investissement à Risque or SUIR, enables venture investors to share their experience and provide seed money for young entrepreneurs, while benefiting from a corporate tax exemption and, for sole partners, an income tax exemption, in both cases for ten years.

Young Innovative Enterprise, a new and particularly advantageous status By adopting the Young Innovative Enterprise status, applicable since January 1, 2004, France now has the most attractive tax incentive system for innovation in Europe. JEI status lowers investor risks and increases their return on investment. This flagship measure enables fledgling innovators to reduce their total payroll costs by a fifth.

A new 150M Euros fund to consolidate the venture capital structure: To consolidate the venture capital structure in France and ensure long-term financing for SMEs, the French government, the Caisse des Dépôts et Consignations (CDC), and the European Investment Bank created a new technological fund in October 2005, contributing equally to its Euros 150 million endowment.

For more information on the full range of financial incentives please click here

French healthcare competitive clusters

A new vehicle for French industrial policy, competitive clusters bring together within the same geographical location companies, public and private research centers, and training institutions. They work hand-in-hand with local authorities on strongly innovative technology-oriented projects with international visibility or ambitions. The government will back companies in such clusters through funding, tax exemptions and, for researchers involved in government-approved R&D projects, payroll tax breaks, to the tune of 1.5 billion over a 3-year period.

To view a bigger map of clusters click here

Four reasons to partner with French companies and/or invest in France

• Opportunity to partner with 400 biotechnology companies, with a pipeline of 195 candidates in therapeutic products in 2005 (amongst which 41 products in phase I, 39 in phase II and 7 in phase III of clinical trials).

  
  

• Be a part of one of the 7 world class healthcare clusters in France, availing of world class infrastructures, highly skilled staff and strong government support; in 2004 the life science sector garnered 2,3 billion Euros (25%) of the French budget for civilian R&D.

  
  

• Privileged point of entry for the European market with 2.2 bn Euros turnover in bio-drugs currently in France.

  
  

• France is setting the pace for tax incentives to innovation in Europe: 2/3 of French SME’s already enjoy the status of the Young Innovative Enterprise allowing for full exemption from payroll taxes on employees involved in R&D projects.

How? Let us help you connect with the right people in France:

For more information of how Investing in France can help your business please contact Invest in France Agency.M. Prathik Malhotra, Director of IFA, New Delhi

For any query regarding identification of adequate contacts in France in the Life Science sector, please get in touch with the Consulate General of France - Economic Mission in Mumbai, Shilpa Patil, Consulate General of France -Economic Mission in Mumbai

. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

About Invest in France Agency

Invest in France Agency (IFA) is the national body responsible for promoting, prospecting and facilitating of international investment in France. It also coordinates initiatives promoting the appeal and image of France. The IFA network operates worldwide. It draws on the expertise of specialists in a range of disciplines based at its head office in Paris, as well as offices in North America, Europe and Asia. In France IFA works in partnership with regional development agencies to offer international investors outstanding business opportunities and customized services.

To sponsor future newsletters, write to us

Dr. C Prabhakar, Chief Operating Officer, Rubamin Laboratories Ltd speaks about the strengths and offerings of his company.

Rubamin Laboratories Limited (Formerly Rubamin Pharmaceuticals) is a 100% Export Oriented Unit, engaged in developing, manufacturing and marketing pharmaceutical and fine chemicals. RLL is an ISO 9001, ISO 14001 and OHSAS 18001 accredited facility focusing on Quality, Environment, Health and Safety (QEHS) aspects in totality.

Our customers include Global Innovators and Generic Pharmaceutical companies in US, Europe, Israel, Japan, Latin America, etc.

RLL’s strong focus on Custom Synthesis, development and manufacturing enables it to be part of the entire value chain of the customers – all the way from Drug Development (Pre-clinical to Phase III) to commercial manufacture.

Learn more about Rubamin Labs Ltd.

Fun Trivia:

WIN A PRIZE!

First 5 people to reply correctly to the trivia below will win a prize!

How many steps are there to the summit platform, of the Eiffel Tower, today?
a) 1710
b) 1665
c) 1920
d) 1855

Send us your answer here.

----------------------------

Trivia,Issue 2:
Cologne, the birthplace of Eau-de-Cologne is situated on the banks of which river?

Answer:Cologne is situated on the banks of the "River Rhine".

Congratulations to all the lucky winners!
Christine Chartroux, Dynamit Nobel GmbH; Ed W. Lefler, Dowpharma

----------------------------

Interesting Facts about France:

1) The Eiffel Tower was built in 1889 for an exhibition and was supposed to be only a temporary structure, although it still stands today at 984 feet tall.

2) France boasts over 500 different cheeses

3) Wine is free with most meals (including lunch) but you have to pay for milk for your coffee.

4) The streets run in every possible direction, and the intersections are circular.

5) There are almost as many motorcycles, scooters, and mopeds as cars.

To know more Interesting Facts about France write to us here

CHEMISTRY PUNS

“My name is Bond, Ionic Bond; Taken, not shared!”

What emotional disorder does a gas chomatograph suffer from?
Separation anxiety


........................


It is disconcerting to reflect on the number of students we have flunked in chemistry for not knowing what we later found to be untrue. --Quoted in Robert L. Weber, Science With a Smile (1992)